Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?

Affiliations

Editorial

Chan Hong Jeon. J Rheum Dis. 2022.

. 2022 Oct 1;29(4):191-192.

doi: 10.4078/jrd.22.0034. Epub 2022 Sep 13.

¹ Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.

No abstract available

Conflict of interest statement

CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported.

1. Luque Ramos A, Redeker I, Hoffmann F, Callhoff J, Zink A, Albrecht K. Comorbidities in patients with rheumatoid arthritis and their association with patient-reported outcomes: results of claims data linked to questionnaire survey. J Rheumatol. 2019;46:564–71. doi: 10.3899/jrheum.180668. - DOI - PubMed
1. Joo YB, Jeong SM, Park YJ, Kim KJ, Park KS. Use of disease-modifying antirheumatic drugs after cancer diagnosis in rheumatoid arthritis patients. J Rheum Dis. 2022;29:162–70. doi: 10.4078/jrd.2022.29.3.162. - DOI - PMC - PubMed
1. Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9. - DOI - PMC - PubMed
1. De Cock D, Hyrich K. Malignancy and rheumatoid arthritis: epidemiology, risk factors and management. Best Pract Res Clin Rheumatol. 2018;32:869–86. doi: 10.1016/j.berh.2019.03.011. - DOI - PubMed
1. Warren GW, Cummings KM. Tobacco and lung cancer: risks, trends, and outcomes in patients with cancer. Am Soc Clin Oncol Educ Book. 2013;33:359–64. doi: 10.14694/EdBook_AM.2013.33.359. - DOI - PubMed